Patents Assigned to Vegenics Pty Limited
-
Patent number: 11866739Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.Type: GrantFiled: October 4, 2019Date of Patent: January 9, 2024Assignee: VEGENICS PTY LIMITEDInventors: Michael Gerometta, Timothy Adams
-
Patent number: 11209444Abstract: The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularisation. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.Type: GrantFiled: March 25, 2019Date of Patent: December 28, 2021Assignees: VEGENICS PTY LIMITED, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.Inventors: Megan E. Baldwin, Kameran Lashkari, Jie Ma
-
Patent number: 10494617Abstract: The present invention is directed to polynucleotides that encode VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the encoded ligand binding molecules.Type: GrantFiled: June 30, 2017Date of Patent: December 3, 2019Assignee: VEGENICS PTY LIMITEDInventors: Michael Gerometta, Timothy Adams
-
Patent number: 10274503Abstract: The present application is directed to the use of a VEGF-C inhibitor, a VEGFR-2 inhibitor and/or a VEGFR-3 inhibitor as a prophylactic or therapeutic for the treatment of eye disorders such as a maculopathy and pathogenic ocular neovascularization. The application is also directed to the use of a VEGF-C measurement from a biological sample from a mammalian subject as a predictive marker, a selected marker, a responsive marker or a tracking marker for a disease or condition selected from the group consisting of a maculopathy and pathogenic ocular neovascularization.Type: GrantFiled: May 5, 2014Date of Patent: April 30, 2019Assignees: VEGENICS PTY LIMITED, THE SCHEPENS EYE RESEARCH INSTITUTE, INC.Inventors: Megan E. Baldwin, Kameran Lashkari, Jie Ma
-
Publication number: 20180118804Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.Type: ApplicationFiled: November 21, 2017Publication date: May 3, 2018Applicant: VEGENICS PTY LIMITEDInventors: Kari Alitalo, Karl B. Lemström, Antti I. Nykänen
-
Patent number: 9896499Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.Type: GrantFiled: April 15, 2015Date of Patent: February 20, 2018Assignee: VEGENICS PTY LIMITEDInventors: Kari Alitalo, Karl B. Lemström, Antti I. Nykänen
-
Publication number: 20170349886Abstract: The present invention is directed to polynucleotides that encode VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the encoded ligand binding molecules.Type: ApplicationFiled: June 30, 2017Publication date: December 7, 2017Applicant: VEGENICS PTY LIMITEDInventors: MICHAEL GEROMETTA, TIMOTHY ADAMS
-
Patent number: 9745558Abstract: The present invention is directed to VEGFR-3 ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis. A glycosylation sequon of wildtype VEGFR-3 has been modified to eliminate glycosylation in the ligand binding molecules.Type: GrantFiled: February 13, 2014Date of Patent: August 29, 2017Assignee: VEGENICS PTY LIMITEDInventors: Michael Gerometta, Timothy Adams
-
Patent number: 9260526Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: November 17, 2014Date of Patent: February 16, 2016Assignee: VEGENICS PTY LIMITEDInventors: Kari Alitalo, Taija Makinen
-
Patent number: 9073997Abstract: The present invention provides materials and methods for antagonizing the function of vascular endothelial growth factor receptors, platelet derived growth factor receptors and other receptors, to prevent, inhibit, or ameliorate allograft rejection or arteriosclerosis in organisms that receive an organ transplant.Type: GrantFiled: February 1, 2008Date of Patent: July 7, 2015Assignee: VEGENICS PTY LIMITEDInventors: Kari Alitalo, Karl B. Lemström, Antti I. Nykänen
-
Patent number: 8940695Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: January 6, 2006Date of Patent: January 27, 2015Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Taija Makinen
-
Patent number: 8759286Abstract: Described herein are pharmaceutical compositions comprising a VEGF-D polypeptide.Type: GrantFiled: April 19, 2013Date of Patent: June 24, 2014Assignee: Vegenics Pty LimitedInventors: Marc G. Achen, Stephen A. Stacker, Kari Alitalo, Andrew F. Wilks
-
Publication number: 20140072511Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: ApplicationFiled: April 18, 2013Publication date: March 13, 2014Applicant: VEGENICS PTY LIMITEDInventor: VEGENICS PTY LIMITED
-
Patent number: 8637262Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors; polynucleotides encoding the polypeptides; vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.Type: GrantFiled: October 5, 2012Date of Patent: January 28, 2014Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Vladimir Joukov
-
Publication number: 20130345409Abstract: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it, pharmaceutical compositions containing it, and uses thereof in medical and diagnostic applications.Type: ApplicationFiled: April 19, 2013Publication date: December 26, 2013Applicant: VEGENICS PTY LIMITEDInventor: Vegenics Pty Limited
-
Publication number: 20130224766Abstract: Provided are purified and isolated VEGF-C polypeptides capable of binding to at least one of KDR receptor tyrosine kinase (VEGFR-2) and Flt4 receptor tyrosine kinase (VEGFR-3); analogs of such peptides that have VEGF-C-like or VEGF-like biological activities or that are VEGF or VEGF-C inhibitors: polynucleotides encoding the polypeptides: vectors and host cells that embody the polynucleotides; pharmaceutical compositions and diagnostic reagents comprising the polypeptides; and methods of making and using the polypeptides. Methods of inhibiting endothelial cell proliferation are also provided.Type: ApplicationFiled: October 5, 2012Publication date: August 29, 2013Applicant: VEGENICS PTY LIMITEDInventor: VEGENICS PTY LIMITED
-
Patent number: 8461109Abstract: The invention also relates to a method for of enhancing the acceptance and/or healing of a skin graft in a subject comprising stimulating angiogenesis and lymphangiogenesis with an effective amount of an isolated VEGF-D polypeptide.Type: GrantFiled: April 17, 2012Date of Patent: June 11, 2013Assignee: Vegenics Pty LimitedInventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
-
Patent number: 8444957Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: February 17, 2010Date of Patent: May 21, 2013Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Arja Kaipainen, Rejia Valtola, Lolla Jussila
-
Publication number: 20130089551Abstract: The invention relates to a method of treatment of pulmonary edema, comprising the step of administering to a subject in need thereof a therapeutically effective amount of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis or inhibiting VEGF-D activity in the subject. The method may comprise the step of identifying a subject at risk of developing pulmonary edema. The invention also relates to an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity for treating pulmonary edema in a subject. Further, the invention relates to use of an agent capable of inhibiting signaling mediated by VEGFR-3, inhibiting lymphangiogenesis, or inhibiting VEGF-D activity in the manufacture of a medicament for treating pulmonary edema in a subject.Type: ApplicationFiled: October 5, 2012Publication date: April 11, 2013Applicant: VEGENICS PTY LIMITEDInventor: VEGENICS PTY LIMITED
-
Patent number: 8383788Abstract: A nucleotide molecule encoding a protein encoded by a Fos regulated gene or a fragment thereof, wherein said protein or fragment thereof is encoded by any one of the nucleotide sequences shown in FIG. 1 or 2 or a fragment thereof, including allelic variants and species variants of the nucleotide sequences.Type: GrantFiled: May 7, 2002Date of Patent: February 26, 2013Assignee: Vegenics Pty LimitedInventor: Salvatore Oliviero